Josefin UlriksdotterCecilia SvedmanMagnus BruzeJenny GlimsjöKajsa KällbergThanisorn SukakulMartin MowitzLunds UniversitetHelsingborgs LasarettFaculty of Medicine, Siriraj Hospital, Mahidol UniversityBlekingesjukhuset2020-08-252020-08-252020-01-01Contact Dermatitis. (2020)16000536010518732-s2.0-85088638175https://repository.li.mahidol.ac.th/handle/123456789/58318© 2020 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd. Background: Several cases of allergic contact dermatitis (ACD) to the glucose sensor FreeStyle Libre have been reported. Isobornyl acrylate (IBOA) and N,N-dimethylacrylamide (DMAA) are known culprit allergens. Objectives: To evaluate patients with suspected ACD to FreeStyle Libre in a standardized manner, present causative allergens, and assess patient-reported implications. Methods: A total of 15 patients with suspected ACD to FreeStyle Libre were patch tested with the Swedish baseline series and a new medical device series. IBOA and DMAA were tested at 0.1% and 0.3% in petrolatum (pet.). Readings were performed on day (D) 3 and D7. Background data, details on skin reactions, and associated implications were assessed using a questionnaire. Results: Thirteen patients were sensitized to IBOA and four to DMAA. Two positive reactions to IBOA and one to DMAA were seen only at 0.3% concentration on D7. Median duration of sensor use before dermatitis onset was 6 months. Half the number of the patients took precautions in everyday life due to sensor-related skin reactions. Six patients discontinued sensor usage. Conclusions: Patients with suspected ACD to glucose sensors should be evaluated with a relevant patch test series containing IBOA and DMAA. Adding the 0.3% pet. concentration is recommended. The reading on D7 is necessary.Mahidol UniversityMedicineArticleSCOPUS10.1111/cod.13649